syk-20210630false2021Q2000031076412/311411310.100.1000003107642021-01-012021-06-300000310764us-gaap:CommonStockMember2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes1.125Due2021Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes0.250Due2024Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes2.125Due2027Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes0.750Due2029Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes2.625Due2030Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes1.000Due2031Member2021-01-012021-06-30xbrli:shares00003107642021-06-30iso4217:USD00003107642021-04-012021-06-3000003107642020-04-012020-06-3000003107642020-01-012020-06-30iso4217:USDxbrli:shares00003107642020-12-310000310764us-gaap:CommonStockMember2021-03-310000310764us-gaap:CommonStockMember2020-03-310000310764us-gaap:CommonStockMember2020-12-310000310764us-gaap:CommonStockMember2019-12-310000310764us-gaap:CommonStockMember2021-04-012021-06-300000310764us-gaap:CommonStockMember2020-04-012020-06-300000310764us-gaap:CommonStockMember2021-01-012021-06-300000310764us-gaap:CommonStockMember2020-01-012020-06-300000310764us-gaap:CommonStockMember2021-06-300000310764us-gaap:CommonStockMember2020-06-300000310764us-gaap:AdditionalPaidInCapitalMember2021-03-310000310764us-gaap:AdditionalPaidInCapitalMember2020-03-310000310764us-gaap:AdditionalPaidInCapitalMember2020-12-310000310764us-gaap:AdditionalPaidInCapitalMember2019-12-310000310764us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300000310764us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300000310764us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-300000310764us-gaap:AdditionalPaidInCapitalMember2020-01-012020-06-300000310764us-gaap:AdditionalPaidInCapitalMember2021-06-300000310764us-gaap:AdditionalPaidInCapitalMember2020-06-300000310764us-gaap:RetainedEarningsMember2021-03-310000310764us-gaap:RetainedEarningsMember2020-03-310000310764us-gaap:RetainedEarningsMember2020-12-310000310764us-gaap:RetainedEarningsMember2019-12-310000310764us-gaap:RetainedEarningsMember2021-04-012021-06-300000310764us-gaap:RetainedEarningsMember2020-04-012020-06-300000310764us-gaap:RetainedEarningsMember2021-01-012021-06-300000310764us-gaap:RetainedEarningsMember2020-01-012020-06-300000310764us-gaap:RetainedEarningsMember2021-06-300000310764us-gaap:RetainedEarningsMember2020-06-300000310764us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310000310764us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310000310764us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000310764us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000310764us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000310764us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300000310764us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300000310764us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-06-300000310764us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000310764us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300000310764us-gaap:ParentMember2021-06-300000310764us-gaap:ParentMember2020-06-300000310764us-gaap:NoncontrollingInterestMember2021-06-300000310764us-gaap:NoncontrollingInterestMember2020-06-3000003107642020-06-3000003107642019-12-310000310764syk:KneesMembersyk:OrthopaedicsMember2021-04-012021-06-300000310764syk:KneesMembersyk:OrthopaedicsMember2020-04-012020-06-300000310764syk:KneesMembersyk:OrthopaedicsMember2021-01-012021-06-300000310764syk:KneesMembersyk:OrthopaedicsMember2020-01-012020-06-300000310764syk:HipsMembersyk:OrthopaedicsMember2021-04-012021-06-300000310764syk:HipsMembersyk:OrthopaedicsMember2020-04-012020-06-300000310764syk:HipsMembersyk:OrthopaedicsMember2021-01-012021-06-300000310764syk:HipsMembersyk:OrthopaedicsMember2020-01-012020-06-300000310764syk:TraumaandExtremitiesMembersyk:OrthopaedicsMember2021-04-012021-06-300000310764syk:TraumaandExtremitiesMembersyk:OrthopaedicsMember2020-04-012020-06-300000310764syk:TraumaandExtremitiesMembersyk:OrthopaedicsMember2021-01-012021-06-300000310764syk:TraumaandExtremitiesMembersyk:OrthopaedicsMember2020-01-012020-06-300000310764syk:OtherOrthopaedicsMembersyk:OrthopaedicsMember2021-04-012021-06-300000310764syk:OtherOrthopaedicsMembersyk:OrthopaedicsMember2020-04-012020-06-300000310764syk:OtherOrthopaedicsMembersyk:OrthopaedicsMember2021-01-012021-06-300000310764syk:OtherOrthopaedicsMembersyk:OrthopaedicsMember2020-01-012020-06-300000310764syk:OrthopaedicsMember2021-04-012021-06-300000310764syk:OrthopaedicsMember2020-04-012020-06-300000310764syk:OrthopaedicsMember2021-01-012021-06-300000310764syk:OrthopaedicsMember2020-01-012020-06-300000310764syk:MedsurgMembersyk:InstrumentsMember2021-04-012021-06-300000310764syk:MedsurgMembersyk:InstrumentsMember2020-04-012020-06-300000310764syk:MedsurgMembersyk:InstrumentsMember2021-01-012021-06-300000310764syk:MedsurgMembersyk:InstrumentsMember2020-01-012020-06-300000310764syk:MedsurgMembersyk:EndoscopyMember2021-04-012021-06-300000310764syk:MedsurgMembersyk:EndoscopyMember2020-04-012020-06-300000310764syk:MedsurgMembersyk:EndoscopyMember2021-01-012021-06-300000310764syk:MedsurgMembersyk:EndoscopyMember2020-01-012020-06-300000310764syk:MedsurgMembersyk:MedicalMember2021-04-012021-06-300000310764syk:MedsurgMembersyk:MedicalMember2020-04-012020-06-300000310764syk:MedsurgMembersyk:MedicalMember2021-01-012021-06-300000310764syk:MedsurgMembersyk:MedicalMember2020-01-012020-06-300000310764syk:MedsurgMembersyk:SustainabilityMember2021-04-012021-06-300000310764syk:MedsurgMembersyk:SustainabilityMember2020-04-012020-06-300000310764syk:MedsurgMembersyk:SustainabilityMember2021-01-012021-06-300000310764syk:MedsurgMembersyk:SustainabilityMember2020-01-012020-06-300000310764syk:MedsurgMember2021-04-012021-06-300000310764syk:MedsurgMember2020-04-012020-06-300000310764syk:MedsurgMember2021-01-012021-06-300000310764syk:MedsurgMember2020-01-012020-06-300000310764syk:NeurotechnologyAndSpineMembersyk:NeurotechnologyMember2021-04-012021-06-300000310764syk:NeurotechnologyAndSpineMembersyk:NeurotechnologyMember2020-04-012020-06-300000310764syk:NeurotechnologyAndSpineMembersyk:NeurotechnologyMember2021-01-012021-06-300000310764syk:NeurotechnologyAndSpineMembersyk:NeurotechnologyMember2020-01-012020-06-300000310764syk:NeurotechnologyAndSpineMembersyk:SpineMember2021-04-012021-06-300000310764syk:NeurotechnologyAndSpineMembersyk:SpineMember2020-04-012020-06-300000310764syk:NeurotechnologyAndSpineMembersyk:SpineMember2021-01-012021-06-300000310764syk:NeurotechnologyAndSpineMembersyk:SpineMember2020-01-012020-06-300000310764syk:NeurotechnologyAndSpineMember2021-04-012021-06-300000310764syk:NeurotechnologyAndSpineMember2020-04-012020-06-300000310764syk:NeurotechnologyAndSpineMember2021-01-012021-06-300000310764syk:NeurotechnologyAndSpineMember2020-01-012020-06-300000310764syk:KneesMembersyk:OrthopaedicsMembercountry:US2021-04-012021-06-300000310764syk:KneesMembersyk:OrthopaedicsMemberus-gaap:NonUsMember2021-04-012021-06-300000310764syk:KneesMembersyk:OrthopaedicsMembercountry:US2020-04-012020-06-300000310764syk:KneesMembersyk:OrthopaedicsMemberus-gaap:NonUsMember2020-04-012020-06-300000310764syk:HipsMembersyk:OrthopaedicsMembercountry:US2021-04-012021-06-300000310764syk:HipsMembersyk:OrthopaedicsMemberus-gaap:NonUsMember2021-04-012021-06-300000310764syk:HipsMembersyk:OrthopaedicsMembercountry:US2020-04-012020-06-300000310764syk:HipsMembersyk:OrthopaedicsMemberus-gaap:NonUsMember2020-04-012020-06-300000310764syk:TraumaandExtremitiesMembersyk:OrthopaedicsMembercountry:US2021-04-012021-06-300000310764syk:TraumaandExtremitiesMembersyk:OrthopaedicsMemberus-gaap:NonUsMember2021-04-012021-06-300000310764syk:TraumaandExtremitiesMembersyk:OrthopaedicsMembercountry:US2020-04-012020-06-300000310764syk:TraumaandExtremitiesMembersyk:OrthopaedicsMemberus-gaap:NonUsMember2020-04-012020-06-300000310764syk:OtherOrthopaedicsMembersyk:OrthopaedicsMembercountry:US2021-04-012021-06-300000310764syk:OtherOrthopaedicsMembersyk:OrthopaedicsMemberus-gaap:NonUsMember2021-04-012021-06-300000310764syk:OtherOrthopaedicsMembersyk:OrthopaedicsMembercountry:US2020-04-012020-06-300000310764syk:OtherOrthopaedicsMembersyk:OrthopaedicsMemberus-gaap:NonUsMember2020-04-012020-06-300000310764syk:OrthopaedicsMembercountry:US2021-04-012021-06-300000310764syk:OrthopaedicsMemberus-gaap:NonUsMember2021-04-012021-06-300000310764syk:OrthopaedicsMembercountry:US2020-04-012020-06-300000310764syk:OrthopaedicsMemberus-gaap:NonUsMember2020-04-012020-06-300000310764syk:MedsurgMembersyk:InstrumentsMembercountry:US2021-04-012021-06-300000310764syk:MedsurgMembersyk:InstrumentsMemberus-gaap:NonUsMember2021-04-012021-06-300000310764syk:MedsurgMembersyk:InstrumentsMembercountry:US2020-04-012020-06-300000310764syk:MedsurgMembersyk:InstrumentsMemberus-gaap:NonUsMember2020-04-012020-06-300000310764syk:MedsurgMembersyk:EndoscopyMembercountry:US2021-04-012021-06-300000310764syk:MedsurgMemberus-gaap:NonUsMembersyk:EndoscopyMember2021-04-012021-06-300000310764syk:MedsurgMembersyk:EndoscopyMembercountry:US2020-04-012020-06-300000310764syk:MedsurgMemberus-gaap:NonUsMembersyk:EndoscopyMember2020-04-012020-06-300000310764syk:MedsurgMembersyk:MedicalMembercountry:US2021-04-012021-06-300000310764syk:MedsurgMemberus-gaap:NonUsMembersyk:MedicalMember2021-04-012021-06-300000310764syk:MedsurgMembersyk:MedicalMembercountry:US2020-04-012020-06-300000310764syk:MedsurgMemberus-gaap:NonUsMembersyk:MedicalMember2020-04-012020-06-300000310764syk:MedsurgMembersyk:SustainabilityMembercountry:US2021-04-012021-06-300000310764syk:MedsurgMemberus-gaap:NonUsMembersyk:SustainabilityMember2021-04-012021-06-300000310764syk:MedsurgMembersyk:SustainabilityMembercountry:US2020-04-012020-06-300000310764syk:MedsurgMemberus-gaap:NonUsMembersyk:SustainabilityMember2020-04-012020-06-300000310764syk:MedsurgMembercountry:US2021-04-012021-06-300000310764syk:MedsurgMemberus-gaap:NonUsMember2021-04-012021-06-300000310764syk:MedsurgMembercountry:US2020-04-012020-06-300000310764syk:MedsurgMemberus-gaap:NonUsMember2020-04-012020-06-300000310764syk:NeurotechnologyAndSpineMembersyk:NeurotechnologyMembercountry:US2021-04-012021-06-300000310764syk:NeurotechnologyAndSpineMemberus-gaap:NonUsMembersyk:NeurotechnologyMember2021-04-012021-06-300000310764syk:NeurotechnologyAndSpineMembersyk:NeurotechnologyMembercountry:US2020-04-012020-06-300000310764syk:NeurotechnologyAndSpineMemberus-gaap:NonUsMembersyk:NeurotechnologyMember2020-04-012020-06-300000310764syk:NeurotechnologyAndSpineMembersyk:SpineMembercountry:US2021-04-012021-06-300000310764syk:NeurotechnologyAndSpineMemberus-gaap:NonUsMembersyk:SpineMember2021-04-012021-06-300000310764syk:NeurotechnologyAndSpineMembersyk:SpineMembercountry:US2020-04-012020-06-300000310764syk:NeurotechnologyAndSpineMemberus-gaap:NonUsMembersyk:SpineMember2020-04-012020-06-300000310764syk:NeurotechnologyAndSpineMembercountry:US2021-04-012021-06-300000310764syk:NeurotechnologyAndSpineMemberus-gaap:NonUsMember2021-04-012021-06-300000310764syk:NeurotechnologyAndSpineMembercountry:US2020-04-012020-06-300000310764syk:NeurotechnologyAndSpineMemberus-gaap:NonUsMember2020-04-012020-06-300000310764country:US2021-04-012021-06-300000310764us-gaap:NonUsMember2021-04-012021-06-300000310764country:US2020-04-012020-06-300000310764us-gaap:NonUsMember2020-04-012020-06-300000310764syk:KneesMembersyk:OrthopaedicsMembercountry:US2021-01-012021-06-300000310764syk:KneesMembersyk:OrthopaedicsMemberus-gaap:NonUsMember2021-01-012021-06-300000310764syk:KneesMembersyk:OrthopaedicsMembercountry:US2020-01-012020-06-300000310764syk:KneesMembersyk:OrthopaedicsMemberus-gaap:NonUsMember2020-01-012020-06-300000310764syk:HipsMembersyk:OrthopaedicsMembercountry:US2021-01-012021-06-300000310764syk:HipsMembersyk:OrthopaedicsMemberus-gaap:NonUsMember2021-01-012021-06-300000310764syk:HipsMembersyk:OrthopaedicsMembercountry:US2020-01-012020-06-300000310764syk:HipsMembersyk:OrthopaedicsMemberus-gaap:NonUsMember2020-01-012020-06-300000310764syk:TraumaandExtremitiesMembersyk:OrthopaedicsMembercountry:US2021-01-012021-06-300000310764syk:TraumaandExtremitiesMembersyk:OrthopaedicsMemberus-gaap:NonUsMember2021-01-012021-06-300000310764syk:TraumaandExtremitiesMembersyk:OrthopaedicsMembercountry:US2020-01-012020-06-300000310764syk:TraumaandExtremitiesMembersyk:OrthopaedicsMemberus-gaap:NonUsMember2020-01-012020-06-300000310764syk:OtherOrthopaedicsMembersyk:OrthopaedicsMembercountry:US2021-01-012021-06-300000310764syk:OtherOrthopaedicsMembersyk:OrthopaedicsMemberus-gaap:NonUsMember2021-01-012021-06-300000310764syk:OtherOrthopaedicsMembersyk:OrthopaedicsMembercountry:US2020-01-012020-06-300000310764syk:OtherOrthopaedicsMembersyk:OrthopaedicsMemberus-gaap:NonUsMember2020-01-012020-06-300000310764syk:OrthopaedicsMembercountry:US2021-01-012021-06-300000310764syk:OrthopaedicsMemberus-gaap:NonUsMember2021-01-012021-06-300000310764syk:OrthopaedicsMembercountry:US2020-01-012020-06-300000310764syk:OrthopaedicsMemberus-gaap:NonUsMember2020-01-012020-06-300000310764syk:MedsurgMembersyk:InstrumentsMembercountry:US2021-01-012021-06-300000310764syk:MedsurgMembersyk:InstrumentsMemberus-gaap:NonUsMember2021-01-012021-06-300000310764syk:MedsurgMembersyk:InstrumentsMembercountry:US2020-01-012020-06-300000310764syk:MedsurgMembersyk:InstrumentsMemberus-gaap:NonUsMember2020-01-012020-06-300000310764syk:MedsurgMembersyk:EndoscopyMembercountry:US2021-01-012021-06-300000310764syk:MedsurgMemberus-gaap:NonUsMembersyk:EndoscopyMember2021-01-012021-06-300000310764syk:MedsurgMembersyk:EndoscopyMembercountry:US2020-01-012020-06-300000310764syk:MedsurgMemberus-gaap:NonUsMembersyk:EndoscopyMember2020-01-012020-06-300000310764syk:MedsurgMembersyk:MedicalMembercountry:US2021-01-012021-06-300000310764syk:MedsurgMemberus-gaap:NonUsMembersyk:MedicalMember2021-01-012021-06-300000310764syk:MedsurgMembersyk:MedicalMembercountry:US2020-01-012020-06-300000310764syk:MedsurgMemberus-gaap:NonUsMembersyk:MedicalMember2020-01-012020-06-300000310764syk:MedsurgMembersyk:SustainabilityMembercountry:US2021-01-012021-06-300000310764syk:MedsurgMemberus-gaap:NonUsMembersyk:SustainabilityMember2021-01-012021-06-300000310764syk:MedsurgMembersyk:SustainabilityMembercountry:US2020-01-012020-06-300000310764syk:MedsurgMemberus-gaap:NonUsMembersyk:SustainabilityMember2020-01-012020-06-300000310764syk:MedsurgMembercountry:US2021-01-012021-06-300000310764syk:MedsurgMemberus-gaap:NonUsMember2021-01-012021-06-300000310764syk:MedsurgMembercountry:US2020-01-012020-06-300000310764syk:MedsurgMemberus-gaap:NonUsMember2020-01-012020-06-300000310764syk:NeurotechnologyAndSpineMembersyk:NeurotechnologyMembercountry:US2021-01-012021-06-300000310764syk:NeurotechnologyAndSpineMemberus-gaap:NonUsMembersyk:NeurotechnologyMember2021-01-012021-06-300000310764syk:NeurotechnologyAndSpineMembersyk:NeurotechnologyMembercountry:US2020-01-012020-06-300000310764syk:NeurotechnologyAndSpineMemberus-gaap:NonUsMembersyk:NeurotechnologyMember2020-01-012020-06-300000310764syk:NeurotechnologyAndSpineMembersyk:SpineMembercountry:US2021-01-012021-06-300000310764syk:NeurotechnologyAndSpineMemberus-gaap:NonUsMembersyk:SpineMember2021-01-012021-06-300000310764syk:NeurotechnologyAndSpineMembersyk:SpineMembercountry:US2020-01-012020-06-300000310764syk:NeurotechnologyAndSpineMemberus-gaap:NonUsMembersyk:SpineMember2020-01-012020-06-300000310764syk:NeurotechnologyAndSpineMembercountry:US2021-01-012021-06-300000310764syk:NeurotechnologyAndSpineMemberus-gaap:NonUsMember2021-01-012021-06-300000310764syk:NeurotechnologyAndSpineMembercountry:US2020-01-012020-06-300000310764syk:NeurotechnologyAndSpineMemberus-gaap:NonUsMember2020-01-012020-06-300000310764country:US2021-01-012021-06-300000310764us-gaap:NonUsMember2021-01-012021-06-300000310764country:US2020-01-012020-06-300000310764us-gaap:NonUsMember2020-01-012020-06-300000310764us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-03-310000310764us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-03-310000310764us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-03-310000310764us-gaap:AccumulatedTranslationAdjustmentMember2021-03-3100003107642021-03-310000310764us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-04-012021-06-300000310764us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-04-012021-06-300000310764us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-04-012021-06-300000310764us-gaap:AccumulatedTranslationAdjustmentMember2021-04-012021-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-04-012021-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-04-012021-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-04-012021-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMember2021-04-012021-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000310764us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-06-300000310764us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-06-300000310764us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-06-300000310764us-gaap:AccumulatedTranslationAdjustmentMember2021-06-300000310764us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-03-310000310764us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-03-310000310764us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-03-310000310764us-gaap:AccumulatedTranslationAdjustmentMember2020-03-3100003107642020-03-310000310764us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-04-012020-06-300000310764us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-04-012020-06-300000310764us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-04-012020-06-300000310764us-gaap:AccumulatedTranslationAdjustmentMember2020-04-012020-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-04-012020-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-04-012020-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-04-012020-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMember2020-04-012020-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300000310764us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-06-300000310764us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-06-300000310764us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-06-300000310764us-gaap:AccumulatedTranslationAdjustmentMember2020-06-300000310764us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310000310764us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310000310764us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-12-310000310764us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000310764us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-06-300000310764us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-06-300000310764us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-01-012021-06-300000310764us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-01-012021-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300000310764us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310000310764us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310000310764us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-12-310000310764us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000310764us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-06-300000310764us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-06-300000310764us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-01-012020-06-300000310764us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-01-012020-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-06-300000310764us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-06-300000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2021-06-300000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2021-06-300000310764us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2021-06-300000310764us-gaap:ForeignExchangeContractMember2021-06-300000310764us-gaap:ForeignExchangeContractMember2021-01-012021-06-300000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2021-06-300000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2021-06-300000310764us-gaap:NondesignatedMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2021-06-300000310764us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2021-06-300000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2021-06-300000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMember2021-06-300000310764us-gaap:NondesignatedMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMember2021-06-300000310764us-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMember2021-06-300000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2021-06-300000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2021-06-300000310764us-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2021-06-300000310764us-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2021-06-300000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2021-06-300000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2021-06-300000310764us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2021-06-300000310764us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2021-06-300000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2020-12-310000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2020-12-310000310764us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2020-12-310000310764us-gaap:ForeignExchangeContractMember2020-12-310000310764us-gaap:ForeignExchangeContractMember2020-01-012020-12-310000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2020-12-310000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2020-12-310000310764us-gaap:NondesignatedMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2020-12-310000310764us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2020-12-310000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2020-12-310000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMember2020-12-310000310764us-gaap:NondesignatedMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMember2020-12-310000310764us-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMember2020-12-310000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2020-12-310000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2020-12-310000310764us-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2020-12-310000310764us-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2020-12-310000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2020-12-310000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2020-12-310000310764us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2020-12-310000310764us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2020-12-31iso4217:EUR0000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2021-06-300000310764us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2021-04-012021-06-300000310764us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2020-04-012020-06-300000310764us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2021-01-012021-06-300000310764us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2020-01-012020-06-300000310764us-gaap:NetInvestmentHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-04-012021-06-300000310764us-gaap:NetInvestmentHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-04-012020-06-300000310764us-gaap:NetInvestmentHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-06-300000310764us-gaap:NetInvestmentHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-01-012020-06-300000310764us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-04-012021-06-300000310764us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-04-012020-06-300000310764us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-06-300000310764us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-01-012020-06-300000310764us-gaap:ForeignExchangeContractMember2021-04-012021-06-300000310764us-gaap:ForeignExchangeContractMember2020-04-012020-06-300000310764us-gaap:ForeignExchangeContractMember2020-01-012020-06-300000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2021-01-012021-06-300000310764us-gaap:InterestRateSwapMember2021-01-012021-06-300000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-06-300000310764us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-01-012021-06-300000310764us-gaap:FairValueInputsLevel1Member2021-06-300000310764us-gaap:FairValueInputsLevel1Member2020-12-310000310764us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2021-06-300000310764us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2020-12-310000310764us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-06-300000310764us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310000310764us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2021-06-300000310764us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2020-12-310000310764us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtSecuritiesMember2021-06-300000310764us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtSecuritiesMember2020-12-310000310764us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2021-06-300000310764us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2020-12-310000310764us-gaap:FairValueInputsLevel2Member2021-06-300000310764us-gaap:FairValueInputsLevel2Member2020-12-310000310764us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2021-06-300000310764us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2020-12-310000310764us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMember2021-06-300000310764us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMember2020-12-310000310764us-gaap:FairValueInputsLevel3Member2020-12-310000310764us-gaap:FairValueInputsLevel3Member2019-12-310000310764us-gaap:FairValueInputsLevel3Member2021-01-012021-06-300000310764us-gaap:FairValueInputsLevel3Member2020-01-012020-12-310000310764us-gaap:FairValueInputsLevel3Member2021-06-300000310764srt:MinimumMember2021-06-300000310764srt:MaximumMember2021-06-30xbrli:pure0000310764syk:WrightMember2020-11-012020-11-3000003107642020-11-012020-11-300000310764syk:WrightMember2020-12-310000310764syk:WrightMembersyk:CustomerAndDistributorRelationshipsMember2020-12-310000310764us-gaap:DevelopedTechnologyRightsMembersyk:WrightMember2020-12-310000310764syk:WrightMemberus-gaap:TradeNamesMember2020-12-310000310764syk:WrightMember2020-01-012020-12-310000310764us-gaap:CommercialPaperMembersrt:MaximumMember2021-06-300000310764us-gaap:CommercialPaperMember2021-01-012021-06-30utr:Rate0000310764syk:SeniorUnsecuredNotes2625Due2021Member2021-06-300000310764syk:SeniorUnsecuredNotes2625Due2021Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes2625Due2021Member2020-12-310000310764syk:SeniorUnsecuredNotes1.125Due2021Member2021-06-300000310764syk:SeniorUnsecuredNotes1.125Due2021Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes1.125Due2021Member2020-12-310000310764syk:SeniorUnsecuredNotes0600Due2023Member2021-06-300000310764syk:SeniorUnsecuredNotes0600Due2023Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes0600Due2023Member2020-12-310000310764syk:SeniorUnsecuredNotes3.375due2024Member2021-06-300000310764syk:SeniorUnsecuredNotes3.375due2024Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes3.375due2024Member2020-12-310000310764syk:SeniorUnsecuredNotes0.250Due2024Member2021-06-300000310764syk:SeniorUnsecuredNotes0.250Due2024Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes0.250Due2024Member2020-12-310000310764syk:SeniorUnsecuredNotes1.150Due2025Member2021-06-300000310764syk:SeniorUnsecuredNotes1.150Due2025Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes1.150Due2025Member2020-12-310000310764syk:SeniorUnsecuredNotes3.375due2025MemberMember2021-06-300000310764syk:SeniorUnsecuredNotes3.375due2025MemberMember2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes3.375due2025MemberMember2020-12-310000310764syk:SeniorUnsecuredNotes350Due2026Member2021-06-300000310764syk:SeniorUnsecuredNotes350Due2026Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes350Due2026Member2020-12-310000310764syk:SeniorUnsecuredNotes2.125Due2027Member2021-06-300000310764syk:SeniorUnsecuredNotes2.125Due2027Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes2.125Due2027Member2020-12-310000310764syk:SeniorUnsecuredNotes3650Due2028Member2021-06-300000310764syk:SeniorUnsecuredNotes3650Due2028Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes3650Due2028Member2020-12-310000310764syk:SeniorUnsecuredNotes0.750Due2029Member2021-06-300000310764syk:SeniorUnsecuredNotes0.750Due2029Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes0.750Due2029Member2020-12-310000310764syk:SeniorUnsecuredNotes1.950Due2030Member2021-06-300000310764syk:SeniorUnsecuredNotes1.950Due2030Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes1.950Due2030Member2020-12-310000310764syk:SeniorUnsecuredNotes2.625Due2030Member2021-06-300000310764syk:SeniorUnsecuredNotes2.625Due2030Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes2.625Due2030Member2020-12-310000310764syk:SeniorUnsecuredNotes1.000Due2031Member2021-06-300000310764syk:SeniorUnsecuredNotes1.000Due2031Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes1.000Due2031Member2020-12-310000310764syk:SeniorUnsecuredNotes410Due2043Member2021-06-300000310764syk:SeniorUnsecuredNotes410Due2043Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes410Due2043Member2020-12-310000310764syk:SeniorUnsecuredNotes4.375due2044Member2021-06-300000310764syk:SeniorUnsecuredNotes4.375due2044Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes4.375due2044Member2020-12-310000310764syk:SeniorUnsecuredNotes4625Due2046Member2021-06-300000310764syk:SeniorUnsecuredNotes4625Due2046Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes4625Due2046Member2020-12-310000310764syk:SeniorUnsecuredNotes2.900due2050Member2021-06-300000310764syk:SeniorUnsecuredNotes2.900due2050Member2021-01-012021-06-300000310764syk:SeniorUnsecuredNotes2.900due2050Member2020-12-310000310764syk:TermLoanMember2021-01-012021-06-300000310764syk:TermLoanMember2021-06-300000310764syk:TermLoanMember2020-12-310000310764syk:SeniorUnsecuredNotes2625Due2021Member2021-03-310000310764us-gaap:OperatingSegmentsMembersyk:OrthopaedicsMember2021-04-012021-06-300000310764us-gaap:OperatingSegmentsMembersyk:OrthopaedicsMember2020-04-012020-06-300000310764us-gaap:OperatingSegmentsMembersyk:OrthopaedicsMember2021-01-012021-06-300000310764us-gaap:OperatingSegmentsMembersyk:OrthopaedicsMember2020-01-012020-06-300000310764us-gaap:OperatingSegmentsMembersyk:MedsurgMember2021-04-012021-06-300000310764us-gaap:OperatingSegmentsMembersyk:MedsurgMember2020-04-012020-06-300000310764us-gaap:OperatingSegmentsMembersyk:MedsurgMember2021-01-012021-06-300000310764us-gaap:OperatingSegmentsMembersyk:MedsurgMember2020-01-012020-06-300000310764us-gaap:OperatingSegmentsMembersyk:NeurotechnologyAndSpineMember2021-04-012021-06-300000310764us-gaap:OperatingSegmentsMembersyk:NeurotechnologyAndSpineMember2020-04-012020-06-300000310764us-gaap:OperatingSegmentsMembersyk:NeurotechnologyAndSpineMember2021-01-012021-06-300000310764us-gaap:OperatingSegmentsMembersyk:NeurotechnologyAndSpineMember2020-01-012020-06-300000310764us-gaap:OperatingSegmentsMember2021-04-012021-06-300000310764us-gaap:OperatingSegmentsMember2020-04-012020-06-300000310764us-gaap:OperatingSegmentsMember2021-01-012021-06-300000310764us-gaap:OperatingSegmentsMember2020-01-012020-06-300000310764us-gaap:CorporateNonSegmentMember2021-04-012021-06-300000310764us-gaap:CorporateNonSegmentMember2020-04-012020-06-300000310764us-gaap:CorporateNonSegmentMember2021-01-012021-06-300000310764us-gaap:CorporateNonSegmentMember2020-01-012020-06-300000310764us-gaap:MaterialReconcilingItemsMember2021-04-012021-06-300000310764us-gaap:MaterialReconcilingItemsMember2020-04-012020-06-300000310764us-gaap:MaterialReconcilingItemsMember2021-01-012021-06-300000310764us-gaap:MaterialReconcilingItemsMember2020-01-012020-06-300000310764srt:ScenarioForecastMember2021-01-012021-12-3100003107642020-01-012020-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
| | | | | |
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2021
OR
| | | | | |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission file number: 001-13149
STRYKER CORPORATION
(Exact name of registrant as specified in its charter)
| | | | | | | | | | | | | | | | | | | | | | | |
Michigan | | | | | | 38-1239739 |
(State of incorporation) | | | | | | (I.R.S. Employer Identification No.) |
| | | | | | | |
2825 Airview Boulevard | Kalamazoo, | Michigan | | 49002 |
(Address of principal executive offices) | | (Zip Code) |
| | | | | | | |
| | (269) | 385-2600 | | |
(Registrant’s telephone number, including area code) |
| | | | | | | | |
Securities registered pursuant to Section 12(b) of the Act: |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, $.10 Par Value | SYK | New York Stock Exchange |
1.125% Notes due 2023 | SYK23 | New York Stock Exchange |
0.250% Notes due 2024 | SYK24A | New York Stock Exchange |
2.125% Notes due 2027 | SYK27 | New York Stock Exchange |
0.750% Notes due 2029 | SYK29 | New York Stock Exchange |
2.625% Notes due 2030 | SYK30 | New York Stock Exchange |
1.000% Notes due 2031 | SYK31 | New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | | | | | | | | | | | | | |
Large accelerated filer | ☒ | | Accelerated filer | ☐ | | Emerging growth company | ☐ |
Non-accelerated filer | ☐ | | Small reporting company | ☐ | | | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
There were 377,096,272 shares of Common Stock, $0.10 par value, on June 30, 2021.
| | | | | | | | |
STRYKER CORPORATION | | 2021 Second Quarter Form 10-Q |
PART I – FINANCIAL INFORMATION
| | | | | |
ITEM 1. | FINANCIAL STATEMENTS |
Stryker Corporation and Subsidiaries
CONSOLIDATED STATEMENTS OF EARNINGS (LOSS) (Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months | | Six Months |
| 2021 | | 2020 | | 2021 | | 2020 |
Net sales | $ | 4,294 | | | $ | 2,764 | | | $ | 8,247 | | | $ | 6,352 | |
Cost of sales | 1,522 | | | 1,216 | | | 2,966 | | | 2,473 | |
Gross profit | $ | 2,772 | | | $ | 1,548 | | | $ | 5,281 | | | $ | 3,879 | |
Research, development and engineering expenses | 310 | | | 233 | | | 598 | | | 487 | |
Selling, general and administrative expenses | 1,505 | | | 1,225 | | | 3,080 | | | 2,555 | |
Recall charges | 76 | | | — | | | 82 | | | (6) | |
Amortization of intangible assets | 149 | | | 110 | | | 330 | | | 228 | |
Total operating expenses | $ | 2,040 | | | $ | 1,568 | | | $ | 4,090 | | | $ | 3,264 | |
Operating income (loss) | $ | 732 | | | $ | (20) | | | $ | 1,191 | | | $ | 615 | |
Other income (expense), net | (70) | | | (67) | | | (162) | | | (112) | |
Earnings (loss) before income taxes | $ | 662 | | | $ | (87) | | | $ | 1,029 | | | $ | 503 | |
Income taxes | 70 | | | (4) | | | 135 | | | 93 | |
Net earnings (loss) | $ | 592 | | | $ | (83) | | | $ | 894 | | | $ | 410 | |
| | | | | | | |
Net earnings (loss) per share of common stock: | | | | | | | |
Basic | $ | 1.57 | | | $ | (0.22) | | | $ | 2.37 | | | $ | 1.09 | |
Diluted | $ | 1.55 | | | $ | (0.22) | | | $ | 2.34 | | | $ | 1.08 | |
| | | | | | | |
Weighted-average shares outstanding (in millions): | | | | | | | |
Basic | 376.9 | | | 375.5 | | | 376.6 | | | 375.1 | |
Effect of dilutive employee stock compensation | 5.4 | | | — | | | 5.4 | | | 4.8 | |
Diluted | 382.3 | | | 375.5 | | | 382.0 | | | 379.9 | |
| | | | | | | |
Cash dividends declared per share of common stock | $ | 0.63 | | | $ | 0.575 | | | $ | 1.26 | | | $ | 1.15 | |
Anti-dilutive shares excluded from the calculation of dilutive employee stock options were 4.3 for the three months 2020 and de minimis in all other periods.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months | | Six Months |
| 2021 | | 2020 | | 2021 | | 2020 |
Net earnings (loss) | $ | 592 | | | $ | (83) | | | $ | 894 | | | $ | 410 | |
Other comprehensive income (loss), net of tax: | | | | | | | |
| | | | | | | |
Pension plans | (4) | | | (4) | | | 3 | | | (8) | |
Unrealized gains (losses) on designated hedges | 8 | | | (30) | | | 36 | | | (56) | |
Financial statement translation | (80) | | | (58) | | | 175 | | | (45) | |
Total other comprehensive income (loss), net of tax | $ | (76) | | | $ | (92) | | | $ | 214 | | | $ | (109) | |
Comprehensive income (loss) | $ | 516 | | | $ | (175) | | | $ | 1,108 | | | $ | 301 | |
See accompanying notes to Consolidated Financial Statements.
| | | | | |
Dollar amounts are in millions except per share amounts or as otherwise specified. | 1 |
| | | | | | | | |
STRYKER CORPORATION | | 2021 Second Quarter Form 10-Q |
CONSOLIDATED BALANCE SHEETS
| | | | | | | | | | | |
| June 30 | | December 31 |
| 2021 | | 2020 |
| (Unaudited) | | |
Assets | | | |
Current assets | | | |
Cash and cash equivalents | $ | 2,241 | | | $ | 2,943 | |
Marketable securities | 84 | | | 81 | |
Accounts receivable, less allowance of $141 ($131 in 2020) | 2,714 | | | 2,701 | |
Inventories: | | | |
Materials and supplies | 658 | | | 678 | |
Work in process | 264 | | | 251 | |
Finished goods | 2,509 | | | 2,565 | |
Total inventories | $ | 3,431 | | | $ | 3,494 | |
Prepaid expenses and other current assets | 562 | | | 488 | |
Total current assets | $ | 9,032 | | | $ | 9,707 | |
Property, plant and equipment: | | | |
Land, buildings and improvements | 1,607 | | | 1,546 | |
Machinery and equipment | 3,755 | | | 3,636 | |
Total property, plant and equipment | $ | 5,362 | | | $ | 5,182 | |
Less accumulated depreciation | 2,624 | | | 2,430 | |
Property, plant and equipment, net | $ | 2,738 | | | $ | 2,752 | |
Goodwill | 12,802 | | | 12,778 | |
Other intangibles, net | 5,261 | | | 5,554 | |
Noncurrent deferred income tax assets | 1,751 | | | 1,530 | |
Other noncurrent assets | 2,114 | | | 2,009 | |
Total assets | $ | 33,698 | | | $ | 34,330 | |
| | | |
Liabilities and shareholders' equity | | | |
Current liabilities | | | |
Accounts payable | $ | 864 | | | $ | 810 | |
Accrued compensation | 890 | | | 925 | |
Income taxes | 300 | | | 207 | |
Dividends payable | 238 | | | 237 | |
Accrued product liabilities | 444 | | | 515 | |
Accrued expenses and other liabilities | 1,510 | | | 1,586 | |
Current maturities of debt | 6 | | | 761 | |
Total current liabilities | $ | 4,252 | | | $ | 5,041 | |
Long-term debt, excluding current maturities | 12,734 | | | 13,230 | |
Income taxes | 927 | | | 990 | |
Other noncurrent liabilities | 1,965 | | | 1,985 | |
Total liabilities | $ | 19,878 | | | $ | 21,246 | |
Shareholders' equity | | | |
Common stock, $0.10 par value | 38 | | | 38 | |
Additional paid-in capital | 1,844 | | | 1,741 | |
Retained earnings | 12,881 | | | 12,462 | |
Accumulated other comprehensive loss | (943) | | | (1,157) | |
Total shareholders' equity | $ | 13,820 | | | $ | 13,084 | |
Total liabilities and shareholders' equity | $ | 33,698 | | | $ | 34,330 | |
See accompanying notes to Consolidated Financial Statements.
| | | | | |
Dollar amounts are in millions except per share amounts or as otherwise specified. | 2 |
| | | | | | | | |
STRYKER CORPORATION | | 2021 Second Quarter Form 10-Q |
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months | | Six Months |
| 2021 | | 2020 | | 2021 | | 2020 |
Common stock shares outstanding (in millions) | | | | | | | |
Beginning | 376.7 | | | 375.4 | | | 376.1 | | | 374.5 | |
Issuance of common stock under stock compensation and benefit plans | 0.4 | | | 0.2 | | | 1.0 | | | 1.1 | |
Repurchase of common stock | — | | | — | | | — | | | — | |
Ending | 377.1 | | | 375.6 | | | 377.1 | | | 375.6 | |
| | | | | | | |
Common stock | | | | | | | |
Beginning | $ | 38 | | | $ | 38 | | | $ | 38 | | | $ | 37 | |
Issuance of common stock under stock compensation and benefit plans | — | | | — | | | — | | | 1 | |
Repurchase of common stock | — | | | — | | | — | | | — | |
Ending | $ | 38 | | | $ | 38 | | | $ | 38 | | | $ | 38 | |
Additional paid-in capital | | | | | | | |
Beginning | $ | 1,806 | | | $ | 1,676 | | | $ | 1,741 | | | $ | 1,628 | |
Issuance of common stock under stock compensation and benefit plans | (1) | | | — | | | (4) | | | (8) | |
Repurchase of common stock | — | | | — | | | — | | | — | |
Share-based compensation | 39 | | | 30 | | | 107 | | | 86 | |
Ending | $ | 1,844 | | | $ | 1,706 | | | $ | 1,844 | | | $ | 1,706 | |
Retained earnings | | | | | | | |
Beginning | $ | 12,525 | | | $ | 12,024 | | | $ | 12,462 | | | $ | 11,748 | |
| | | | | | | |
Net earnings (loss) | 592 | | | (83) | | | 894 | | | 410 | |
Repurchase of common stock | — | | | — | | | — | | | — | |
Cash dividends declared | (236) | | | (216) | | | (475) | | | (433) | |
Ending | $ | 12,881 | | | $ | 11,725 | | | $ | 12,881 | | | $ | 11,725 | |
Accumulated other comprehensive income (loss) | | | | | | | |
Beginning | $ | (867) | | | $ | (623) | | | $ | (1,157) | | | $ | (606) | |
Other comprehensive income (loss) | (76) | | | (92) | | | 214 | | | (109) | |
Ending | $ | (943) | | | $ | (715) | | | $ | (943) | | | $ | (715) | |
Total Stryker shareholders' equity | $ | 13,820 | | | $ | 12,754 | | | $ | 13,820 | | | $ | 12,754 | |
Non-controlling interest | — | | | — | | | — | | | — | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Total shareholders' equity | $ | 13,820 | | | $ | 12,754 | | | $ | 13,820 | | | $ | 12,754 | |
See accompanying notes to Consolidated Financial Statements.
| | | | | |
Dollar amounts are in millions except per share amounts or as otherwise specified. | 3 |
| | | | | | | | |
STRYKER CORPORATION | | 2021 Second Quarter Form 10-Q |
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
| | | | | | | | | | | |
| Six Months |
| 2021 | | 2020 |
Operating activities | | | |
Net earnings | $ | 894 | | | $ | 410 | |
Adjustments to reconcile net earnings to net cash provided by operating activities: | | | |
Depreciation | 187 | | | 163 | |
Amortization of intangible assets | 330 | | | 228 | |
Asset impairments | 3 | | | 161 | |
Share-based compensation | 107 | | | 86 | |
Recall charges | 82 | | | (6) | |
Sale of inventory stepped-up to fair value at acquisition | 137 | | | 9 | |
Changes in operating assets and liabilities: | | | |
Accounts receivable | (24) | | | 671 | |
Inventories | (128) | | | (181) | |
Accounts payable | 57 | | | (34) | |
Accrued expenses and other liabilities | 22 | | | (375) | |
Recall-related payments | (163) | | | (12) | |
Income taxes | (98) | | | (39) | |
Other, net | (76) | | | 130 | |
Net cash provided by operating activities | $ | 1,330 | | | $ | 1,211 | |
Investing activities | | | |
Acquisitions, net of cash acquired | (104) | | | (26) | |
Purchases of marketable securities | (31) | | | (23) | |
Proceeds from sales of marketable securities | 28 | | | 31 | |
Purchases of property, plant and equipment | (189) | | | (253) | |
Other investing, net | (2) | | | (9) | |
Net cash used in investing activities | $ | (298) | | | $ | (280) | |
Financing activities | | | |
Proceeds (payments) on short-term borrowings, net | (7) | | | 8 | |
Proceeds from issuance of long-term debt | 5 | | | 2,293 | |
Payments on long-term debt | (1,151) | | | (500) | |
Dividends paid | (475) | | | (431) | |
Repurchases of common stock | — | | | — | |
Cash paid for taxes from withheld shares | (74) | | | (68) | |
Other financing, net | (27) | | | (14) | |
Net cash provided by (used in) financing activities | $ | (1,729) | | | $ | 1,288 | |
Effect of exchange rate changes on cash and cash equivalents | (5) | | | (17) | |
Change in cash and cash equivalents | $ | (702) | | | $ | 2,202 | |
Cash and cash equivalents at beginning of period | 2,943 | | | 4,337 | |
Cash and cash equivalents at end of period | $ | 2,241 | | | $ | 6,539 | |
See accompanying notes to Consolidated Financial Statements.
| | | | | |
Dollar amounts are in millions except per share amounts or as otherwise specified. | 4 |
| | | | | | | | |
STRYKER CORPORATION | | 2021 Second Quarter Form 10-Q |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
NOTE 1 - BASIS OF PRESENTATION
General Information
Management believes the accompanying unaudited Consolidated Financial Statements contain all adjustments, including normal recurring items, considered necessary to fairly present the financial position of Stryker Corporation and its consolidated subsidiaries ("Stryker," the "Company," "we," us" or "our") on June 30, 2021 and the results of operations for the three and six months 2021. The results of operations included in these Consolidated Financial Statements may not necessarily be indicative of our annual results. These statements should be read in conjunction with our Annual Report on Form 10-K for 2020.
New Accounting Pronouncements Not Yet Adopted
We evaluate all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in our disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on our Consolidated Financial Statements.
NOTE 2 - REVENUE RECOGNITION
Our policies for recognizing sales have not changed from those described in our Annual Report on Form 10-K for 2020.
We disaggregate our net sales by product line and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors.
| | | | | | | | | | | | | | | | | |
Net Sales by Product Line | | | | | |
| Three Months | | Six Months |
| 2021 | 2020 | | 2021 | 2020 |
Orthopaedics: | | | | | |
Knees | $ | 474 | | $ | 241 | | | $ | 886 | | $ | 673 | |
Hips | 353 | | 216 | | | 662 | | 532 | |
Trauma and Extremities | 674 | | 330 | | | 1,314 | | 722 | |
Other | 127 | | 107 | | | 250 | | 189 | |
| $ | 1,628 | | $ | 894 | | | $ | 3,112 | | $ | 2,116 | |
MedSurg: | | | | | |
Instruments | $ | 517 | | $ | 328 | | | $ | 986 | | $ | 841 | |
Endoscopy | 518 | | 316 | | | 987 | | 771 | |
Medical | 640 | | 632 | | | 1,262 | | 1,219 | |
Sustainability | 73 | | 48 | | | 134 | | 115 | |
| $ | 1,748 | | $ | 1,324 | | | $ | 3,369 | | $ | 2,946 | |
Neurotechnology and Spine: | | | | | |
Neurotechnology | $ | 611 | | $ | 369 | | | $ | 1,181 | | $ | 852 | |
Spine | 307 | | 177 | | | 585 | | 438 | |
| $ | 918 | | $ | 546 | | | $ | 1,766 | | $ | 1,290 | |
Total | $ | 4,294 | | $ | 2,764 | | | $ | 8,247 | | $ | 6,352 | |
| | | | | | | | | | | | | | | | | |
Net Sales by Geography | | | | | |
| Three Months 2021 | | Three Months 2020 |
| United States | International | | United States | International |
Orthopaedics: | | | | | |
Knees | $ | 349 | | $ | 125 | | | $ | 179 | | $ | 62 | |
Hips | 221 | | 132 | | | 140 | | 76 | |
Trauma and Extremities | 475 | | 199 | | | 208 | | 122 | |
Other | 99 | | 28 | | | 96 | | 11 | |
| $ | 1,144 | | $ | 484 | | | $ | 623 | | $ | 271 | |
MedSurg: | | | | | |
Instruments | $ | 401 | | $ | 116 | | | $ | 249 | | $ | 79 | |
Endoscopy | 407 | | 111 | | | 253 | | 63 | |
Medical | 488 | | 152 | | | 454 | | 178 | |
Sustainability | 72 | | 1 | | | 48 | | — | |
| $ | 1,368 | | $ | 380 | | | $ | 1,004 | | $ | 320 | |
Neurotechnology and Spine: | | | | | |
Neurotechnology | $ | 371 | | $ | 240 | | | $ | 211 | | $ | 158 | |
Spine | 217 | | 90 | | | 128 | | 49 | |
| $ | 588 | | $ | 330 | | | $ | 339 | | $ | 207 | |
Total | $ | 3,100 | | $ | 1,194 | | | $ | 1,966 | | $ | 798 | |
| | | | | | | | | | | | | | | | | |
Net Sales by Geography | | | | | |
| Six Months 2021 | | Six Months 2020 |
| United States | International | | United States | International |
Orthopaedics: | | | | | |
Knees | $ | 643 | | $ | 243 | | | $ | 501 | | $ | 172 | |
Hips | 407 | | 255 | | | 341 | | 191 | |
Trauma and Extremities | 915 | | 399 | | | 468 | | 254 | |
Other | 193 | | 57 | | | 165 | | 24 | |
| $ | 2,158 | | $ | 954 | | | $ | 1,475 | | $ | 641 | |
MedSurg: | | | | | |
Instruments | $ | 756 | | $ | 230 | | | $ | 659 | | $ | 182 | |
Endoscopy | 761 | | 226 | | | 617 | | 154 | |
Medical | 961 | | 301 | | | 908 | | 311 | |
Sustainability | 132 | | 2 | | | 114 | | 1 | |
| $ | 2,610 | | $ | 759 | | | $ | 2,298 | | $ | 648 | |
Neurotechnology and Spine: | | | | | |
Neurotechnology | $ | 706 | | $ | 475 | | | $ | 512 | | $ | 340 | |
Spine | 410 | | 175 | | | 324 | | 114 | |
| $ | 1,116 | | $ | 650 | | | $ | 836 | | $ | 454 | |
Total | $ | 5,884 | | $ | 2,363 | | | $ | 4,609 | | $ | 1,743 | |
Contract Assets and Liabilities
On June 30, 2021 and December 31, 2020 contract assets recorded in our Consolidated Balance Sheets were not significant.
Our contract liabilities arise as a result of consideration received from customers at inception of contracts for certain businesses or where the timing of billing for services precedes satisfaction of our performance obligations. We generally satisfy performance obligations within one year from the contract inception date. Our contract liabilities were $476 and $416 on June 30, 2021 and December 31, 2020.
| | | | | |
Dollar amounts are in millions except per share amounts or as otherwise specified. | 5 |
| | | | | | | | |
STRYKER CORPORATION | | 2021 Second Quarter Form 10-Q |
NOTE 3 - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (AOCI)
| | | | | | | | | | | | | | | | | |
Three Months 2021 | Marketable Securities | Pension Plans | Hedges | Financial Statement Translation | Total |
Beginning | $ | (3) | | $ | (252) | | $ | 18 | | $ | (630) | | $ | (867) | |
OCI | — | | (9) | | 7 | | (75) | | (77) | |
Income taxes | — | | 2 | | (3) | | 2 | | 1 | |
Reclassifications to: | | | | | |
Cost of sales | — | | — | | 4 | | — | | 4 | |
Other (income) expense | — | | 4 | | (1) | | (9) | | (6) | |
Income taxes | — | | (1) | | 1 | | 2 | | 2 | |
Net OCI | $ | — | | $ | (4) | | $ | 8 | | $ | (80) | | $ | (76) | |
Ending | $ | (3) | | $ | (256) | | $ | 26 | | $ | (710) | | $ | (943) | |
| | | | | | | | | | | | | | | | | |
Three Months 2020 | Marketable Securities | Pension Plans | Hedges | Financial Statement Translation | Total |
Beginning | $ | (3) | | $ | (183) | | $ | 21 | | $ | (458) | | $ | (623) | |
OCI | (1) | | (8) | | (33) | | (91) | | (133) | |
Income taxes | — | | 2 | | 8 | | 39 | | 49 | |
Reclassifications to: | | | | | |
Cost of sales | — | | — | | (3) | | — | | (3) | |
Other (income) expense | 1 | | 3 | | (2) | | (7) | | (5) | |
Income taxes | — | | (1) | | — | | 1 | | — | |
Net OCI | $ | — | | $ | (4) | | $ | (30) | | $ | (58) | | $ | (92) | |
Ending | $ | (3) | | $ | (187) | | $ | (9) | | $ | (516) | | $ | (715) | |
| | | | | | | | | | | | | | | | | |
Six Months 2021 | Marketable Securities | Pension Plans | Hedges | Financial Statement Translation | Total |
Beginning | $ | (3) | | $ | (259) | | $ | (10) | | $ | (885) | | $ | (1,157) | |
OCI | — | | (1) | | 34 | | 198 | | 231 | |
Income taxes | — | | (2) | | (11) | | (10) | | (23) | |
Reclassifications to: | | | | | |
Cost of sales | — | | — | | 5 | | — | | 5 | |
Other (income) expe |